Persistent use of Analgesic Medications in Mild-to-Moderate Alzheimer’s Disease
- 127 Downloads
Background and Objectives
Previous studies have reported a lower use of analgesics in patients with Alzheimer’s disease (AD) than in non-AD elderly. To date, no study has focused on persistent analgesic use in patients with mild-to-moderate AD.
The “Réseau sur la maladie d’Alzheimer Français” (REAL.FR) cohort study enrolled community-dwelling patients with mild-to-moderate AD. Persistent analgesic use was defined as the consumption of at least one analgesic drug during two consecutive visits (6 months). Associated factors were identified in a nested case–control study.
In REAL.FR, 595 patients were present during at least two consecutive visits [mean age = 77.5 ± 6.8 years, mini-mental state examination (MMSE) = 20.1 ± 4.2]. Prevalence of persistent analgesic use was 13.1 % (95 % CI = 10.4–15.9). The incidence of persistent analgesic use was 5.9/100 patient-years (95 % CI = 5.2–6.6). Women (adjusted odds ratio [OR] = 3.1, 95 % CI = 1.2–8.1), patients with musculoskeletal disorders (OR = 3.4, 95 % CI = 1.6–7.3) and patients treated with numerous medications (OR = 3.0, 95 % CI = 1.5–5.8) were more likely to use analgesics persistently. Statistically significant associations were found with disease duration and disease progression but not with AD severity at baseline.
Our results suggest a low use of analgesics in AD patients, which could vary with AD progression.
The REAL.FR Study group refers to: Vellas B., Ousset PJ., Gillette-Guyonnet S., Nourhashemi F., Andrieu S. (Toulouse); Rainfray M., Richard-Harston S. (Bordeaux); Franco A., Couturier P. (Grenoble); Pasquier F., Mackowiak-Cordoliani M.A. (Lille); Frigard B., Idiri H., Gallouj K. (Wasquehal); Michel B. (Marseille); Jeandel Cl. (Montpellier); Touchon J., Portet F., Lerouge S. (Montpellier); Robert P., Brocker P., Bertogliati C. (Nice); Forette B., Teillet L., Lechowski L. (Paris); Belmin J., Pariel-Madjlelssi S. (Paris); Verny M., Artaz M.A. (Paris); Forette F., Rigaud A.S., Latour F. (Paris); Jouanny P., Belliard S., Michel O. (Rennes); Gonthier G., Girtanner C., Thomas-Anterion C. (Saint Etienne). The DSA group refers to: Andrieu S., Savy S., Cantet C., Coley N.
REAL.FR was supported by a grant from the French Ministry of Health (PHRC 98-47N and PHRC 18-05). Promotion of the REAL.FR study was supported by the University Hospital Centre of Toulouse. The data sharing activity was supported by the “Association Monegasque pour la recherche sur la maladie d’Alzheimer” (AMPA) and the UMR 1027 Unit INSERM – University of Toulouse III. The funding organizations were not involved in the design or conduct of the study, data collection, management, analysis or interpretation, nor in the preparation, review, or approval of the manuscript.
The authors have no conflicts of interest relevant to the content of this study.
- 24.American Psychiatric A. Diagnostic and statistical manual of mental disorders. 4th ed. Washington, DC: American Psychiatric Association; 1994.Google Scholar
- 27.Rosen WG, Mohs RC, Davis KL. A new rating scale for Alzheimer’s disease. A J Psychiatry. 1984;141(11):1356–64.Google Scholar
- 32.Methodology WHOCCfDS. ATC-DDD index. [cited 2012 March 6]. Available from: http://www.whocc.no/atc_ddd_index/.
- 35.Scherder EJ. Low use of analgesics in Alzheimer’s disease: possible mechanisms. Psychiatry. 2000;63(1):1–12.Google Scholar